Organigram Global Inc Dossier - Source-backed chat

Organigram Global Inc

OGIToronto Stock Exchange

SectorHealth Care

IndustryPharmaceuticals

Beta (adjusted)1.61

Intrinsic Value $1.27median of 2 methodsbased on filings through 30 Sep 2024

Market Price $0.98Price as of 1 Oct 2026

UndervaluedIntrinsic value is 30% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $138.5M

Enterprise Value $83.8M

Shares Outstanding 144.2M diluted

Next Earnings Date17 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Organigram Global Inc. represents a compelling turnaround and growth story in the global cannabis sector. Despite a challenging Q2 Fiscal 2026 marked by operational headwinds in vapes and pre-rolls, the company has established a unique footprint as the only pure-play cannabis operator with leadership positions in both Canada and Germany. The strategic acquisition of Sanity Group, combined with a fortified balance sheet backed by British American Tobacco (BAT), positions Organigram to capture high-margin international growth as regulatory frameworks evolve.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.4420%

Persistent operational challenges and market share erosion in Canada, coupled with slower-than-expected integration of Sanity Group. Delays in EU-GMP certification limit international export growth, keeping free cash flow in negative territory and depressing valuation multiples.

Base CaseCentral scenario

$3.1350%

Stabilization of the Canadian recreational market share through resolved operational issues in vapes and pre-rolls. Sanity Group contributes steady quarterly revenue of approximately €25 million, enabling Organigram to meet its updated Fiscal 2026 guidance of over $350 million in net revenue, positive/breakeven free cash flow, and improved Adjusted EBITDA.

Bull CaseUpside scenario

$3.2530%

Rapid international scaling driven by the consolidation of Sanity Group in Germany and successful EU-GMP certification of the Moncton facility. This unlocks high-margin export volumes to Europe and Australia, driving net revenue well above the $350 million guidance and expanding Adjusted EBITDA margins toward historical highs.

Scenarios reflect our research view at the research date.

Key Investment Merits

Dual-market leadership in Canada (#1 market share in vapes, concentrates, and milled flower) and Germany (via Sanity Group).
Strong balance sheet and strategic backing from British American Tobacco (BAT), providing capital and corporate governance support.
Significant international growth runway with guided average quarterly revenue of €25 million from Sanity Group.

Key Investment Risks

Operational execution risks, as evidenced by the Q2 Fiscal 2026 product specification and return issues.
Intense price competition and consumer preference shifts in the Canadian adult-use market.
Regulatory and compliance hurdles in international jurisdictions, particularly regarding import/export certifications.

Thesis Invalidation Triggers

Failure of Sanity Group to meet the guided €25 million average quarterly revenue contribution.
Inability to secure EU-GMP certification for the Moncton facility within the projected timeline.
Continued deterioration of Canadian recreational market share and gross margins below 30%.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.